Allosteric modulator

Allosteric modulator

AMPA receptor- Allosteric Modulation

Positive allosteric modulator plot

Positive allosteric modulator agonist plot

Positive allosteric modulator antagonist plot

Allosteric modulator refers to a substance that indirectly influences (modulates) the effects of a primary ligand that directly activates or inhibits the function of a target protein, such as an enzyme or receptor. Unlike orthosteric modulators, which bind to the active site of a protein, allosteric modulators bind to a different site, known as the allosteric site. This binding causes a conformational change in the protein structure, which can enhance (positive allosteric modulator, or PAM) or reduce (negative allosteric modulator, or NAM) the activity of the protein in the presence of the primary ligand. Allosteric modulators are of significant interest in pharmacology and drug design because they offer a means to modulate protein function in a more nuanced manner than traditional active site-directed drugs.

Mechanism of Action

The mechanism of action of allosteric modulators involves the binding to specific sites on a protein that are distinct from the active site where the primary ligand binds. This allosteric site can be located at a considerable distance from the active site, and the binding of an allosteric modulator to this site induces a conformational change in the protein structure. This change can either increase (in the case of PAMs) or decrease (in the case of NAMs) the affinity of the active site for the primary ligand or alter the maximal effect produced by the ligand.

Types of Allosteric Modulators

There are two main types of allosteric modulators:

• Positive Allosteric Modulators (PAMs): These enhance the effects of the primary ligand. They can increase the affinity of the receptor for the ligand or increase the efficacy of the ligand, leading to an enhanced response.
• Negative Allosteric Modulators (NAMs): These decrease the effects of the primary ligand. They can reduce the affinity of the receptor for the ligand or decrease the efficacy of the ligand, leading to a diminished response.

Clinical Significance

Allosteric modulators have significant potential in the development of new therapeutic agents. They offer several advantages over traditional drugs that act on the active site of proteins, including greater specificity, reduced side effects, and the ability to fine-tune the activity of a protein rather than simply turning it on or off. This makes them particularly attractive for the treatment of diseases where the modulation of protein function, rather than complete inhibition or activation, is desired.

Examples

Some well-known examples of allosteric modulators include:

• Benzodiazepines, which are PAMs of the GABA_A receptor. They enhance the effect of GABA, the primary inhibitory neurotransmitter in the brain, and are used to treat anxiety, insomnia, and seizures.
• Cinacalcet, a PAM of the calcium-sensing receptor (CaSR) used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Research and Development

The field of allosteric modulation is an area of active research and development in pharmacology. Identifying and characterizing allosteric sites on proteins, understanding the mechanisms by which allosteric modulators exert their effects, and developing new allosteric modulators are key areas of focus. This research has the potential to lead to the development of novel therapeutics for a wide range of diseases.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian